MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
2.630
+0.080 (3.14%)
Apr 17, 2025, 4:00 PM EDT - Market closed
MaxCyte Employees
MaxCyte had 114 employees as of December 31, 2024. The number of employees decreased by 29 or -20.28% compared to the previous year.
Employees
114
Change (1Y)
-29
Growth (1Y)
-20.28%
Revenue / Employee
$338,833
Profits / Employee
-$360,132
Market Cap
272.00M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
MXCT News
- 8 days ago - MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - GlobeNewsWire
- 4 weeks ago - MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price - Seeking Alpha
- 5 weeks ago - MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance - GlobeNewsWire
- 2 months ago - MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - GlobeNewsWire
- 2 months ago - MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference - GlobeNewsWire
- 2 months ago - Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) - Business Wire
- 2 months ago - MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments - GlobeNewsWire